Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (“GPCR”) oral small molecule drug discovery powered by our proprietary Native Complex Platform®. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
In the company’s own words · 10-K filed Mar 9, 2026 · SEC EDGAR
Septerna, Inc. (SEPN) reported revenue of $27M in Q1 2026 (quarter ended March 31, 2026), up 12011% from the same quarter a year earlier. That came with net loss of $8.6M. For the full year FY2025, revenue was $46M (+4175% year on year) and net income −$49M.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.